Rubicon Research shareholders passed all nine resolutions at the 27th Annual General Meeting held on August 26, 2026, including approval of FY26 financial results and a scheme to merge wholly owned subsidiary KIA Health Tech Private Limited with the parent entity.

The meeting was held through video conferencing, with 71 members attending. A total of 41,330 shareholders were on record as of the cut-off date of August 19, 2026, representing 16,55,31,908 shares. Voting was conducted via remote e-voting (open from August 22 to August 25, 2026) and e-voting at the AGM. Sunny Gogiya of SGGS & Associates served as Scrutinizer, appointed by the Board at its meeting on July 20, 2026.

AGM voting summary

All nine resolutions were passed with requisite majority. The following table summarises the resolutions and their outcomes.

Detailed voting results

The table below presents votes cast in favour and against each resolution, based on the Scrutinizer's Consolidated Report dated August 26, 2026.

The merger of KIA Health Tech (Resolution 9) required a 90% majority under Section 233 of the Companies Act, 2013, and was passed accordingly. The two ESOP resolutions (6 and 7) drew the highest opposition among institutional public shareholders, with 18.03% and 17.69% of institutional votes cast against, respectively, though both passed comfortably overall.

Financial performance

The company reported consolidated revenue from operations of ₹17,540 million for FY26, a 37% increase from ₹12,843 million in FY25. Net profit after tax rose to ₹2,467 million, up from ₹1,344 million in the prior year.

Operating EBITDA pre R&D expanded to ₹5,938 million, representing 34% of operating revenue, compared to 30% in FY25. R&D expenses increased to ₹1,935 million (11% of revenue) from ₹1,325 million (10% of revenue).

Balance sheet position

Shareholders' funds grew significantly to ₹12,888 million as of March 31, 2026, from ₹5,410 million in March 2025. Borrowings decreased to ₹2,594 million from ₹3,932 million. Cash and cash equivalents stood at ₹3,460 million, up from ₹1,162 million.

What the numbers show

Product concentration has declined steadily. The top five products contributed 34% of revenue in FY26, down from 56% in FY23. Similarly, the top ten products accounted for 53% of revenue in FY26, compared to 77% in FY23, indicating a broadening portfolio base.

Corporate actions

Mr. Parag Sancheti, Executive Director & CEO, conducted the proceedings in the absence of Chairman Mr. Venkat Changavalli. The meeting included presentations on the company's evolution from a service provider to a specialty products manufacturer. Directors present included Mrs. Pratibha Pilgaonkar, Mr. K G Ananthakrishnan, Mr. Milind Patil, and Mr. Shantanu Rastogi. MUFG Intime India Private Limited serves as the Registrar and Share Transfer Agent of the company.

Rubicon Research reported a substantial rise in profitability for the first quarter of FY27, with net profit jumping 96% year-on-year to ₹848 million. This compares to a net profit of ₹433 million in the corresponding period of the previous fiscal year. The company’s top-line growth was equally robust, with revenue increasing by 51% to ₹5.3 billion from ₹3.5 billion in the prior year’s first quarter.

The surge in revenue was accompanied by an expansion in operating margins, signaling improved cost management or higher-value mix in its services. During the earnings call held on August 14, 2026, management highlighted that the strong performance included the consolidation of Arinna Lifesciences, which contributed approximately INR12 crores to revenue with no material impact on EBITDA.

Financial Performance Highlights

EBITDA rose to ₹1.29 billion from ₹791 million year-on-year, representing a growth of approximately 63%. More notably, the EBITDA margin expanded by 172 basis points to 24.15%, up from 22.43% in the same quarter last year. Pre-R&D EBITDA margin stood at 35%, up from 32.5% in the prior year. R&D expenses were recorded at INR580 million, translating to 10.9% of revenue.

Strategic Updates and Guidance

Management provided several strategic updates during the conference call. The company revised its full-year FY27 EBITDA margin guidance upwards from an earlier range of 22-23% to a comfortable 23%, despite expected cost impacts from new ESOP schemes, Arinna integration, and pre-revenue costs for new facilities.

Key developments include:

• US Expansion: Rubicon acquired a manufacturing site in East Brunswick, New Jersey, via a court-supervised bankruptcy process for USD2.9 million. The facility, which shares a wall with the company’s distribution operations, is expected to begin commercialization in calendar year 2027. It aims to serve specialty products and US government departments requiring onshore manufacturing.
• Pithampur Facility: The FDA issued Form 483 with two procedural observations during an unannounced inspection in July. Management filed appropriate responses and received FDA approval on a regulatory filing post-inspection. Commercial operations are on track to ramp up from the first quarter of calendar year 2027.
• Leadership Changes: Nitin Jajodia transitions from CFO to Chief Commercial Officer. Rohit will join as CFO designate before moving into the CFO role upon Nitin’s transition.

Operational Efficiency and Cash Flow

Gross margin increased sequentially by around 140 bps to 67.7%, despite rising input and freight costs due to geopolitical conditions. This improvement followed tactical measures taken in previous quarters to reduce reliance on lower-margin contract manufacturing. USD revenues for Q1 were USD55 million, up 32% year-on-year from USD42 million, though there was a slight sequential drop due to these tactical mix changes.

Operating cash flow before working capital change was INR1,390 million, while cash flow from operating activities stood at INR285 million. Management noted that this figure was impacted by delays in GST refunds, which are expected to normalize in Q2. Net working capital days improved to 114 days as on June 30, 2026, from 126 days as on March 31, 2026, though management cautioned against reading too much into quarterly fluctuations.

What the Numbers Show

The divergence between revenue growth (51%) and net profit growth (96%) indicates a leverage effect where fixed costs are being spread over a larger revenue base, or variable costs have decreased as a percentage of sales. The simultaneous expansion in EBITDA margin confirms that the profit growth is operationally driven rather than resulting from one-time gains or tax benefits. The company appears to be scaling efficiently, converting incremental revenue into disproportionately higher bottom-line earnings. Additionally, the strategic shift away from lower-margin outsourced manufacturing towards in-house production is beginning to yield margin improvements, as evidenced by the sequential gross margin expansion.

Existing Snippets: []